Clinical Trial

Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study

Study acronym: ADIPOSA
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to test if bexagliflozin lowers the sleep apnea severity in adults who are overweight or obese with moderate to severe obstructive sleep apnea (OSA) compared with a placebo (look-alike substance that contains no active drug). The main question it aims to answer is: * If SGLT2i will reduce anatomic and physiologic traits, clinical measures of OSA and sleep deficiency in participants * If improvement in clinical measures are because of improvement in the anatomic and physiologic traits. Participants will be placed on either drug or placebo and get routine normal care for 6 months. At the start and end of the study, participants will undergo different clinical measurements to see if the drug makes the sleep apnea better.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-11-03; most recent amendment 2025-09-03.
Status change: Not Yet Recruiting → Recruiting 2024-04-12
Trial Details
NCT Number NCT05612594
Lead Sponsor Yale University
Collaborators: Case Western Reserve University
Conditions Sleep Apnea
Enrollment 164 participants
Start Date 2024-03-27
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2025-09-11